Cerenis Therapeutics has advanced its lead clinical candidate, CER-001, into Phase III development across Europe and North America to evaluate efficacy to regress atherosclerosis, and safety of CER-001 in patients with Familial Primary HypoalphAlipoproteinemia (FPHA), a rare orphan disease.   CER-001 is an engineered complex of recombinant human apoA-I, the major structural protein of High-Density Lipoprotein (HDL) and phospholipids. Development of CER-001 leverages Catalent’s GPEx technology,...